Industries · B2B healthcare · Clinical diagnostics

A clinical diagnostics marketing agency for companies selling tests to labs and hospitals

For IVD, molecular, lab instrument and digital pathology companies: marketing built on your validation data and written for the lab directors and pathologists who check it.

Senior-led and billed by the hour, with a 30-day cancellation notice. Your first call is with a co-founder.

165
high-intent target contacts active on LinkedIn for Coforix, which sells generative AI to hospitals, in the first ABM program it ran with us. More client results are on our customers page.
Healthcare and life science companies we've helped

The diagnostics market in 2026

$113B
global in vitro diagnostics market in 2025, with the US accounting for 41% of sales (Kalorama Information, 2025)
~10x
as many tests need a notified body certificate under the EU's IVDR as under the directive it replaced (MedTech Europe, 2021)
28.5%
vacancy rate in US anatomic pathology departments, the highest of any lab department (ASCP 2024 Vacancy Survey)
31%
of US healthcare organizations that changed their lab services in the past year broadened their test menu (Siemens Healthineers and YouGov, 2026)
The job

Why diagnostics marketing needs a specialist

Lab buyers judge a test on its data, its workflow fit and who will pay for it, usually in that order.

Labs buy on data and workflow

Lab directors read sensitivity, specificity and the validation cohort first, then turnaround and hands-on time, since most labs run short-staffed. Copy that opens with adjectives loses them before they reach your data.

Reimbursement decides adoption

A test that performs well can still stall if nobody pays for it. Payers, lab benefit managers and hospital finance teams ask what the result changes for the patient and what each result costs, and your marketing has to answer both.

Two rulebooks, two launch plans

IVDR in Europe and FDA rules in the US limit what you can claim and where. In MedTech Europe's 2024 survey, large IVD makers choosing the EU as their first launch market had dropped by 40% since IVDR, so many companies now plan the two launches separately.

Tenders decide the shortlist

European hospitals buy through tenders scored against criteria set months in advance. If your evidence isn't in the market before the specification is written, your test can be left off the shortlist.

Problems we solve

Problems we solve for diagnostics companies

What founders and sales leaders at diagnostics companies tell us,
and what we do about it.

“We have our CE-IVDR mark, and adoption is still slow.”
What we hear
Certification gets you into the market, while labs still need a reason to switch. We turn your performance data into the comparison a lab director makes against their current test, and put it in front of the labs that run that test today.
What we do
“Our validation data is better than our marketing.”
What we hear
We read your studies and instructions for use, then rebuild your website and sales materials around the numbers a lab checks first: sensitivity, specificity, sample types and turnaround.
What we do
“Our reps carry the whole sales process.”
What we hear
We build pipeline before the rep arrives, with ABM into named labs and hospital groups, so the first meeting is with a lab that has already read your data.
What we do
“Europe knows our test, and US labs have never heard of it.”
What we hear
We work out which claims your FDA status allows, then find the reference labs and health systems likely to adopt first and build awareness with them before your US team is hired.
What we do
“Every tender is decided on price.”
What we hear
Price wins when the specification gives evidence no weight. We create the clinical and economic material that lab heads and procurement teams can cite when they write the criteria, months before the tender opens.
What we do
“Our KOL is the only one who can explain the test.”
What we hear
We record your KOL once and turn the session into webinars, short explainers and talks your reps can share, so the explanation reaches labs your KOL will never visit.
What we do

Approach

Diagnostics marketing built on validation data

Your Head of Growth runs five workstreams for IVD, molecular and digital pathology companies, each built on the evidence a lab will check.

Evidence-led content

We turn validation studies, method comparisons and workflow data into pages, posters and case studies a lab director can check against the source. Every figure keeps its study reference, so your regulatory team can approve content quickly.

KOL and congress programs

Plans for ADLM, ESCMID Global and USCAP, or the meetings in your specialty: abstracts, booth and symposium content, meetings booked ahead, and KOL sessions recorded for use after the event.

ABM into lab networks and hospital groups

We list the reference labs, hospital groups and lab networks that should be running your test, then reach lab directors, pathologists and procurement with LinkedIn, content and outreach your reps follow up. Coforix, which sells into hospitals, reached 165 high-intent contacts this way.

Tender-ready assets

Product dossiers, evidence summaries, cost-per-result models and reference site lists, prepared before tenders open so your bid team doesn't rebuild them every time.

Diagnostics SEO and AI search

Pages for the test names, methods and conditions lab staff search for, written so search engines and AI assistants cite your data when someone asks which assay to use.

The rule we work by

If your validation data can't support a sentence, the sentence comes out.

Results

Results for companies with scientific
and clinical buyers

Life science
Cradle sells an AI protein design platform to scientists who test every claim before they adopt a tool. Its CEO became the voice of a LinkedIn thought leadership program, supported by paid campaigns into its priority pharma accounts.
10,000+
organic engagements in the first weeks of the campaigns
60+
high-potential interactions passed to sales every quarter
Healthcare AI
Coforix sells generative AI to hospitals, where the person with the problem, the budget holder and the signer are rarely the same. Its first ABM program with us found all three in each target account and gave each one its own campaign.
165
high-intent target contacts active on LinkedIn
27
engaged leads ready for sales

Both clients sell to experts who check the evidence before they buy. You'll find every figure in their published case studies.

What do they say?

We like to let our customers do the talking.

Your journey

Your first 90 days,
week by week

We don't reuse plans between diagnostics companies. Your Head of Growth writes yours around your test, your evidence and the way labs in your markets buy. The cards show one example: a molecular diagnostics company launching a CE-IVDR-marked panel to hospital labs.

Kick off
●
Day 0

Kickoff is a meeting with your CEO, your head of sales and the person responsible for regulatory claims. You give us access to your site, CRM and ad platforms, and we agree how to report labs engaged and evaluations started.

Onboarding
KPI alignment
Ysabel CamusBerk Kalyoncu
Full audit
●
Weeks 1-2

We speak with lab directors who evaluated your test, read your validation studies and any tenders you lost, trace each claim to its source, and audit your website, search rankings, AI-search presence and CRM.

Lab interviews
Evidence check
CRM review
Michaela RiesBerk KalyoncuYsabel Camus
Strategy & workshops
●
Weeks 3-4

Two workshops with your leadership, medical affairs and R&D decide which claims lead, which KOLs speak for the test and which labs and hospital groups go on the target list.

Positioning
KOL voices
Lab list
Ysabel CamusMichaela RiesBerk Kalyoncu
Quick wins
●
Weeks 4-5

Your test pages get rewritten around the numbers labs check, your regulatory team approves an evidence library, and every evaluation request from the website lands in the CRM tagged by source.

Test pages
Evidence library
Request routing
Berk KalyoncuAlexandru Cojuhari
Test pages go live
●
Week 6+

Each test and platform gets a page with its performance data, sample types, turnaround, workflow fit and the references labs ask for before they request an evaluation.

Performance data
Lab references
AI search
Michaela RiesDaniela GutuAlexandru Cojuhari
Evidence content
●
Week 6+

Your validation studies and KOL talks become webinars, posters, method notes and LinkedIn posts. Your medical affairs team approves each one before it goes out.

Webinars
Method notes
KOL posts
Michaela RiesYsabel Camus
Lab network campaigns
●
Week 6+

Paid LinkedIn and evidence content reach lab directors, pathologists and procurement at the labs on your list, and your reps call the people who download or reply.

Target labs
LinkedIn ads
Rep follow-up
Berk KalyoncuYsabel Camus
Congress plan
●
Week 6+

We choose the congresses where your target labs send people, book meetings before each event and follow up with every lab you met in the weeks after.

Congress list
Booked meetings
Post-event follow-up
Ysabel CamusBerk Kalyoncu
First pipeline report
●
Month 3

Your leadership gets one CRM report showing labs engaged, evaluations requested and evaluations started, with the source of each. Lab adoption takes months, so it also shows which target labs are moving closer to a decision.

Labs engaged
Evaluations
Pipeline value
Ysabel CamusBerk Kalyoncu
?
After day 90

At the end of the quarter we sit down with your leadership, shift budget to the labs and channels that produced evaluations, and stop what didn't.

Review with you
Plan adjusted

Diagnostics marketing
and the markets around it

IVD companies share hospitals and labs with MedTech and research-tool companies, though each sells to a different buyer with different proof.

You are here

Clinical diagnostics

Buyer: lab directors, pathologists and hospital procurement, with payers deciding coverage. Proof: validation data, workflow fit and a reimbursement path.

MedTech

Diagnostic AI and clinical software

Diagnostic AI that runs inside a clinical workflow, along with other software and devices used at the point of care, is covered on our MedTech page.

Life sciences

Research-use tools and reagents

Instruments, reagents and software sold to research labs before any clinical claim are covered on our life science page.

Who you'll work with

The specialists who will plan, write and report
on your diagnostics account.

Team
Ysabel Camus
Ysabel Camus
Head of Growth
James Eisner
James Eisner
Head of Growth
Michaela Ries
Michaela Ries
SEO / GEO Lead
Berk Kalyoncu
Berk Kalyoncu
Performance Specialist
Daniela Gutu
Daniela Gutu
Graphic Designer
Alexandru Cojuhari
Alexandru Cojuhari
Front End & Web Developer
André Antunes
André Antunes
RevOps & AI Lead
Daniel Bilici
Daniel Bilici
Sr. Growth Marketing Manager
Ungated report · Marketing for the Health Tech Industry in 2026

What hospital buyers check before they talk to a vendor.

Marketing for the Health Tech Industry in 2026 report cover

Our health tech report covers how hospital buying committees work and why the evidence bar keeps rising for clinical products.

44%
of 224 digital health companies scored zero on published clinical evidence
6
practitioner interviews behind the report's findings
Read the report
Start with section three, which covers the evidence hospital buyers ask for.
FAQ

Clinical diagnostics marketing agency: questions we get asked

Where we work

Amsterdam and New York, for IVD, molecular, lab instrument and digital pathology companies selling in Europe or the US.

What is diagnostics marketing?
What clinical diagnostics marketing services do you offer?
How do IVDR and FDA rules affect diagnostics marketing claims?
How do you market to lab directors and pathologists?
How do you support tender and procurement processes?
How is diagnostics marketing different from medical device marketing?
Do you work with digital pathology and diagnostic AI companies?
How much does a clinical diagnostics marketing agency cost?
How long does diagnostics marketing take to show results?

Your first call is with a co-founder

The call is 30 minutes with the founder who has the most experience in your industry.

Book a 30-minute call